Superworth

Corbus Pharmaceuticals price to book ratio CRBP

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
0.8×
10-year median
3.9×
Against its 10-year history
15th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.3× to 100×
Peer median
1.6×

Corbus Pharmaceuticals' price to book ratio is 0.8× as of Oct 23, 2026.

That is below its ten-year median of 3.9×, lower than on 85% of days in the last ten years.

Over that time it ranged from 0.3× in Mar 2023 to 100× in Jan 2024.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.8×0.8×2.1×
20251.6×0.4×2.3×
20241.0×1.0×100×
202385.9×0.3×92.5×
20220.3×0.3×1.0×
20211.0×1.0×8.6×
20203.6×1.6×77.5×
201911.8×6.3×18.2×
20187.9×4.1×15.3×
201712.2×6.6×52.4×
201628.2×3.7×28.5×
20155.6×5.3×22.2×
201410.0×10.0×18.2×

Against its peers

Companies in Drug Manufacturers - General nearest Corbus Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
CRBPCorbus Pharmaceuticals0.8×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
ATNMActinium Pharmaceuticals1.6×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Corbus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.